Join IPM at HIV R4P 2018!

We hope you will join IPM in Madrid Oct. 21-25 for the 3rd HIV Research for Prevention (R4P) Conference to learn the latest research on IPM's monthly dapivirine ring and other long-acting products designed to offer women new options to stay HIV-free and protect their sexual and reproductive health, on their own terms.

Find us at the oral presentations listed below and in the Poster Hall, where IPM and our partners will be presenting more than 40 posters on IPM’s work—including new interim data from DREAM, one of two open-label extension studies of the dapivirine ring (P19.48LB, Wed., Oct. 24, 17:30-19:30). Download the full list of presentations here.

And be sure to follow us on Twitter at @IPMicrobicides to keep up with news that catches our eye!

Featured presentations

SA05. Planning for Success: Next Steps for Dapivirine Ring 
Sun., Oct. 21, 14:00-17:00, Burdeos
Satellite session co-hosted by OPTIONS, IPM

OA05.02. Partners, Peers and Rumours as Influencers of Use and Attitudes Towards the Dapivirine Vaginal Ring: Qualitative Data from The Ring Study (IPM 027) (MatCH Research Unit)
Tues., Oct. 23, 13:15-13:30, Londres
Oral abstract session: If I Choose, Will I Use? Products, People and Preferences

OA12.02LB. Safety and pharmacokinetics of dapivirine and levonorgestrel vaginal rings for multipurpose prevention of HIV and pregnancy (Microbicide Trials Network [MTN])
Wed., Oct. 24, 13:15-13:30, Londres 
Oral abstract session: Contraception and HIV Risk: Still Between a Rock and a Hard Place

OA12.06. Risk of HIV-1 acquisition among South African women using a variety of contraceptive methods in a prospective study (MTN)
Wed., Oct. 24, 14:15-14:30, Londres
Oral abstract session: Contraception and HIV Risk: Still Between a Rock and a Hard Place

P19.48LB. HIV-1 incidence, adherence to ring use and safety in an open-label trial of dapivirine vaginal ring – DREAM 
Wed., Oct. 24, 17:30-19:30, Poster Hall
Poster presentation by Annalene Nel, IPM

OA18.03. Ethical Considerations for Involving Adolescents Aged 16-17 in HIV Prevention Clinical Trials: Community Perspectives from Uganda (MTN)
Thurs., Oct. 25, 09:00-09:15, Oxford

Oral abstract session: Opinion 360: Meaningful Engagement from Research to Roll Out

OA23.02. Sensitive Next-Generation Sequencing of HIV-1 from Seroconverters in the MTN-020/ASPIRE Dapivirine Vaginal Ring Study (MTN)
Thurs., Oct. 25, 10:45-11:00, Marsella, Burdeos & Estrasburgo

Oral abstract session: Great Expectations: The Impact of PrEP

OA20.06. The dapivirine and levonorgestrel MPT ring: understanding the levonorgestrel binding reaction with silicone elastomer (Queen’s University Belfast)
Thurs., Oct. 25, 11:45-12:00, Londres

Oral abstract session: Into the Future with Delivery Technologies (co-chaired by Zeda Rosenberg, IPM)

Download the full list of oral and poster presentations (PDF).